First Trust Advisors LP Acquires 63,100 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

First Trust Advisors LP increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 350.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,129 shares of the company's stock after acquiring an additional 63,100 shares during the quarter. First Trust Advisors LP owned about 0.17% of Amphastar Pharmaceuticals worth $3,012,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Barclays PLC lifted its stake in Amphastar Pharmaceuticals by 53.3% in the third quarter. Barclays PLC now owns 74,456 shares of the company's stock valued at $3,613,000 after buying an additional 25,878 shares in the last quarter. World Investment Advisors LLC bought a new position in Amphastar Pharmaceuticals during the third quarter worth about $1,614,000. Nordea Investment Management AB grew its holdings in Amphastar Pharmaceuticals by 4.8% during the fourth quarter. Nordea Investment Management AB now owns 279,714 shares of the company's stock worth $10,386,000 after purchasing an additional 12,851 shares during the period. Arkadios Wealth Advisors increased its position in Amphastar Pharmaceuticals by 5.2% during the fourth quarter. Arkadios Wealth Advisors now owns 27,964 shares of the company's stock worth $1,038,000 after buying an additional 1,379 shares during the last quarter. Finally, Dakota Wealth Management raised its stake in Amphastar Pharmaceuticals by 31.7% in the fourth quarter. Dakota Wealth Management now owns 5,486 shares of the company's stock valued at $204,000 after buying an additional 1,322 shares during the period. Institutional investors own 65.09% of the company's stock.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 5,231 shares of company stock valued at $142,752. Corporate insiders own 27.50% of the company's stock.

Amphastar Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ AMPH traded down $0.89 during midday trading on Friday, hitting $23.76. 170,794 shares of the stock traded hands, compared to its average volume of 473,458. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96. The business has a 50 day moving average price of $25.90 and a two-hundred day moving average price of $35.05. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The company has a market cap of $1.13 billion, a PE ratio of 7.92, a P/E/G ratio of 2.19 and a beta of 0.78.

Analyst Ratings Changes

A number of research firms recently weighed in on AMPH. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Finally, Wells Fargo & Company decreased their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.